nodes	percent_of_prediction	percent_of_DWPC	metapath
Lenalidomide—TNFSF11—embryo—liver cancer	0.017	0.302	CbGeAlD
Lenalidomide—CDH5—embryo—liver cancer	0.0128	0.227	CbGeAlD
Lenalidomide—CRBN—embryo—liver cancer	0.00812	0.144	CbGeAlD
Lenalidomide—Pomalidomide—TNF—liver cancer	0.00663	0.38	CrCbGaD
Lenalidomide—CDH5—liver—liver cancer	0.00591	0.105	CbGeAlD
Lenalidomide—Thalidomide—TNF—liver cancer	0.00427	0.245	CrCbGaD
Lenalidomide—CRBN—liver—liver cancer	0.00376	0.0667	CbGeAlD
Lenalidomide—PTGS2—gall bladder—liver cancer	0.00349	0.062	CbGeAlD
Lenalidomide—Thalidomide—CYP2E1—liver cancer	0.00329	0.189	CrCbGaD
Lenalidomide—Thalidomide—CYP1A1—liver cancer	0.00325	0.186	CrCbGaD
Lenalidomide—PTGS2—embryo—liver cancer	0.00221	0.0393	CbGeAlD
Lenalidomide—ABCB1—embryo—liver cancer	0.00137	0.0243	CbGeAlD
Lenalidomide—PTGS2—liver—liver cancer	0.00102	0.0182	CbGeAlD
Lenalidomide—ABCB1—liver—liver cancer	0.000633	0.0112	CbGeAlD
Lenalidomide—Liver function test abnormal—Doxorubicin—liver cancer	0.000463	0.000744	CcSEcCtD
Lenalidomide—Dry skin—Doxorubicin—liver cancer	0.00046	0.000739	CcSEcCtD
Lenalidomide—Pancreatitis—Epirubicin—liver cancer	0.000459	0.000738	CcSEcCtD
Lenalidomide—Vomiting—Sorafenib—liver cancer	0.000458	0.000737	CcSEcCtD
Lenalidomide—Abdominal pain upper—Doxorubicin—liver cancer	0.000458	0.000736	CcSEcCtD
Lenalidomide—Hypokalaemia—Doxorubicin—liver cancer	0.000457	0.000733	CcSEcCtD
Lenalidomide—Angina pectoris—Epirubicin—liver cancer	0.000456	0.000733	CcSEcCtD
Lenalidomide—Rash—Sorafenib—liver cancer	0.000455	0.00073	CcSEcCtD
Lenalidomide—Dermatitis—Sorafenib—liver cancer	0.000454	0.00073	CcSEcCtD
Lenalidomide—Breast disorder—Doxorubicin—liver cancer	0.000453	0.000728	CcSEcCtD
Lenalidomide—Toxic epidermal necrolysis—Doxorubicin—liver cancer	0.000452	0.000726	CcSEcCtD
Lenalidomide—Aspartate aminotransferase increased—Doxorubicin—liver cancer	0.000452	0.000726	CcSEcCtD
Lenalidomide—Headache—Sorafenib—liver cancer	0.000452	0.000726	CcSEcCtD
Lenalidomide—Bronchitis—Epirubicin—liver cancer	0.000451	0.000724	CcSEcCtD
Lenalidomide—Nasopharyngitis—Doxorubicin—liver cancer	0.000449	0.000721	CcSEcCtD
Lenalidomide—Pancytopenia—Epirubicin—liver cancer	0.000445	0.000715	CcSEcCtD
Lenalidomide—Gastritis—Doxorubicin—liver cancer	0.000444	0.000713	CcSEcCtD
Lenalidomide—Muscular weakness—Doxorubicin—liver cancer	0.000442	0.000711	CcSEcCtD
Lenalidomide—Alanine aminotransferase increased—Doxorubicin—liver cancer	0.000442	0.000711	CcSEcCtD
Lenalidomide—Dysuria—Epirubicin—liver cancer	0.000438	0.000704	CcSEcCtD
Lenalidomide—Neutropenia—Epirubicin—liver cancer	0.000438	0.000704	CcSEcCtD
Lenalidomide—Abdominal distension—Doxorubicin—liver cancer	0.000436	0.000701	CcSEcCtD
Lenalidomide—Upper respiratory tract infection—Epirubicin—liver cancer	0.000436	0.0007	CcSEcCtD
Lenalidomide—Dysphagia—Doxorubicin—liver cancer	0.000434	0.000697	CcSEcCtD
Lenalidomide—Influenza—Doxorubicin—liver cancer	0.000434	0.000697	CcSEcCtD
Lenalidomide—Asthma—Doxorubicin—liver cancer	0.000434	0.000697	CcSEcCtD
Lenalidomide—Pollakiuria—Epirubicin—liver cancer	0.000433	0.000695	CcSEcCtD
Lenalidomide—Nausea—Sorafenib—liver cancer	0.000428	0.000688	CcSEcCtD
Lenalidomide—Photosensitivity reaction—Epirubicin—liver cancer	0.000428	0.000687	CcSEcCtD
Lenalidomide—Weight increased—Epirubicin—liver cancer	0.000426	0.000685	CcSEcCtD
Lenalidomide—Pancreatitis—Doxorubicin—liver cancer	0.000425	0.000683	CcSEcCtD
Lenalidomide—Weight decreased—Epirubicin—liver cancer	0.000424	0.000681	CcSEcCtD
Lenalidomide—Hyperglycaemia—Epirubicin—liver cancer	0.000423	0.000679	CcSEcCtD
Lenalidomide—Angina pectoris—Doxorubicin—liver cancer	0.000422	0.000679	CcSEcCtD
Lenalidomide—Pneumonia—Epirubicin—liver cancer	0.00042	0.000675	CcSEcCtD
Lenalidomide—Infestation—Epirubicin—liver cancer	0.000418	0.000671	CcSEcCtD
Lenalidomide—Infestation NOS—Epirubicin—liver cancer	0.000418	0.000671	CcSEcCtD
Lenalidomide—Bronchitis—Doxorubicin—liver cancer	0.000417	0.00067	CcSEcCtD
Lenalidomide—Stevens-Johnson syndrome—Epirubicin—liver cancer	0.000414	0.000665	CcSEcCtD
Lenalidomide—Pancytopenia—Doxorubicin—liver cancer	0.000412	0.000662	CcSEcCtD
Lenalidomide—Renal failure—Epirubicin—liver cancer	0.000411	0.00066	CcSEcCtD
Lenalidomide—Neuropathy peripheral—Epirubicin—liver cancer	0.00041	0.000658	CcSEcCtD
Lenalidomide—Stomatitis—Epirubicin—liver cancer	0.000407	0.000654	CcSEcCtD
Lenalidomide—Urinary tract infection—Epirubicin—liver cancer	0.000406	0.000652	CcSEcCtD
Lenalidomide—Conjunctivitis—Epirubicin—liver cancer	0.000406	0.000652	CcSEcCtD
Lenalidomide—Dysuria—Doxorubicin—liver cancer	0.000405	0.000651	CcSEcCtD
Lenalidomide—Neutropenia—Doxorubicin—liver cancer	0.000405	0.000651	CcSEcCtD
Lenalidomide—Upper respiratory tract infection—Doxorubicin—liver cancer	0.000403	0.000647	CcSEcCtD
Lenalidomide—Sweating—Epirubicin—liver cancer	0.000401	0.000643	CcSEcCtD
Lenalidomide—Pollakiuria—Doxorubicin—liver cancer	0.000401	0.000643	CcSEcCtD
Lenalidomide—Haematuria—Epirubicin—liver cancer	0.000398	0.00064	CcSEcCtD
Lenalidomide—Photosensitivity reaction—Doxorubicin—liver cancer	0.000396	0.000636	CcSEcCtD
Lenalidomide—Hepatobiliary disease—Epirubicin—liver cancer	0.000395	0.000635	CcSEcCtD
Lenalidomide—Weight increased—Doxorubicin—liver cancer	0.000395	0.000634	CcSEcCtD
Lenalidomide—Epistaxis—Epirubicin—liver cancer	0.000394	0.000633	CcSEcCtD
Lenalidomide—Weight decreased—Doxorubicin—liver cancer	0.000392	0.00063	CcSEcCtD
Lenalidomide—Sinusitis—Epirubicin—liver cancer	0.000392	0.00063	CcSEcCtD
Lenalidomide—Hyperglycaemia—Doxorubicin—liver cancer	0.000391	0.000628	CcSEcCtD
Lenalidomide—Agranulocytosis—Epirubicin—liver cancer	0.00039	0.000626	CcSEcCtD
Lenalidomide—Pneumonia—Doxorubicin—liver cancer	0.000389	0.000625	CcSEcCtD
Lenalidomide—Infestation NOS—Doxorubicin—liver cancer	0.000387	0.000621	CcSEcCtD
Lenalidomide—Infestation—Doxorubicin—liver cancer	0.000387	0.000621	CcSEcCtD
Lenalidomide—Stevens-Johnson syndrome—Doxorubicin—liver cancer	0.000383	0.000616	CcSEcCtD
Lenalidomide—Bradycardia—Epirubicin—liver cancer	0.000382	0.000613	CcSEcCtD
Lenalidomide—Renal failure—Doxorubicin—liver cancer	0.00038	0.000611	CcSEcCtD
Lenalidomide—Neuropathy peripheral—Doxorubicin—liver cancer	0.000379	0.000609	CcSEcCtD
Lenalidomide—Haemoglobin—Epirubicin—liver cancer	0.000377	0.000606	CcSEcCtD
Lenalidomide—Stomatitis—Doxorubicin—liver cancer	0.000377	0.000605	CcSEcCtD
Lenalidomide—Rhinitis—Epirubicin—liver cancer	0.000376	0.000604	CcSEcCtD
Lenalidomide—Conjunctivitis—Doxorubicin—liver cancer	0.000376	0.000604	CcSEcCtD
Lenalidomide—Urinary tract infection—Doxorubicin—liver cancer	0.000376	0.000604	CcSEcCtD
Lenalidomide—Haemorrhage—Epirubicin—liver cancer	0.000375	0.000603	CcSEcCtD
Lenalidomide—Hepatitis—Epirubicin—liver cancer	0.000375	0.000603	CcSEcCtD
Lenalidomide—Hypoaesthesia—Epirubicin—liver cancer	0.000373	0.0006	CcSEcCtD
Lenalidomide—Pharyngitis—Epirubicin—liver cancer	0.000372	0.000598	CcSEcCtD
Lenalidomide—Sweating—Doxorubicin—liver cancer	0.000371	0.000595	CcSEcCtD
Lenalidomide—Urinary tract disorder—Epirubicin—liver cancer	0.00037	0.000595	CcSEcCtD
Lenalidomide—Oedema peripheral—Epirubicin—liver cancer	0.000369	0.000594	CcSEcCtD
Lenalidomide—Haematuria—Doxorubicin—liver cancer	0.000369	0.000592	CcSEcCtD
Lenalidomide—Connective tissue disorder—Epirubicin—liver cancer	0.000369	0.000592	CcSEcCtD
Lenalidomide—Urethral disorder—Epirubicin—liver cancer	0.000368	0.000591	CcSEcCtD
Lenalidomide—Hepatobiliary disease—Doxorubicin—liver cancer	0.000366	0.000587	CcSEcCtD
Lenalidomide—Epistaxis—Doxorubicin—liver cancer	0.000365	0.000586	CcSEcCtD
Lenalidomide—Sinusitis—Doxorubicin—liver cancer	0.000363	0.000583	CcSEcCtD
Lenalidomide—Visual impairment—Epirubicin—liver cancer	0.000361	0.000581	CcSEcCtD
Lenalidomide—Agranulocytosis—Doxorubicin—liver cancer	0.000361	0.00058	CcSEcCtD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—HPGDS—liver cancer	0.00036	0.00119	CbGpPWpGaD
Lenalidomide—Erythema multiforme—Epirubicin—liver cancer	0.000355	0.00057	CcSEcCtD
Lenalidomide—Bradycardia—Doxorubicin—liver cancer	0.000353	0.000568	CcSEcCtD
Lenalidomide—Eye disorder—Epirubicin—liver cancer	0.000351	0.000563	CcSEcCtD
Lenalidomide—Tinnitus—Epirubicin—liver cancer	0.00035	0.000562	CcSEcCtD
Lenalidomide—Haemoglobin—Doxorubicin—liver cancer	0.000349	0.00056	CcSEcCtD
Lenalidomide—Flushing—Epirubicin—liver cancer	0.000348	0.000559	CcSEcCtD
Lenalidomide—Cardiac disorder—Epirubicin—liver cancer	0.000348	0.000559	CcSEcCtD
Lenalidomide—Rhinitis—Doxorubicin—liver cancer	0.000348	0.000559	CcSEcCtD
Lenalidomide—Haemorrhage—Doxorubicin—liver cancer	0.000347	0.000558	CcSEcCtD
Lenalidomide—Hepatitis—Doxorubicin—liver cancer	0.000347	0.000558	CcSEcCtD
Lenalidomide—Hypoaesthesia—Doxorubicin—liver cancer	0.000345	0.000555	CcSEcCtD
Lenalidomide—Pharyngitis—Doxorubicin—liver cancer	0.000344	0.000553	CcSEcCtD
Lenalidomide—Urinary tract disorder—Doxorubicin—liver cancer	0.000343	0.000551	CcSEcCtD
Lenalidomide—ABCB1—Transmembrane transport of small molecules—MYO5B—liver cancer	0.000343	0.00113	CbGpPWpGaD
Lenalidomide—ABCB1—Transmembrane transport of small molecules—SLC9C1—liver cancer	0.000343	0.00113	CbGpPWpGaD
Lenalidomide—PTGS2—Aryl Hydrocarbon Receptor—CDKN1A—liver cancer	0.000342	0.00113	CbGpPWpGaD
Lenalidomide—Oedema peripheral—Doxorubicin—liver cancer	0.000342	0.000549	CcSEcCtD
Lenalidomide—Connective tissue disorder—Doxorubicin—liver cancer	0.000341	0.000548	CcSEcCtD
Lenalidomide—Angiopathy—Epirubicin—liver cancer	0.00034	0.000547	CcSEcCtD
Lenalidomide—Urethral disorder—Doxorubicin—liver cancer	0.00034	0.000547	CcSEcCtD
Lenalidomide—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—CASP3—liver cancer	0.00034	0.00112	CbGpPWpGaD
Lenalidomide—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—IL2—liver cancer	0.00034	0.00112	CbGpPWpGaD
Lenalidomide—Immune system disorder—Epirubicin—liver cancer	0.000339	0.000544	CcSEcCtD
Lenalidomide—Mediastinal disorder—Epirubicin—liver cancer	0.000338	0.000543	CcSEcCtD
Lenalidomide—Chills—Epirubicin—liver cancer	0.000337	0.000541	CcSEcCtD
Lenalidomide—Arrhythmia—Epirubicin—liver cancer	0.000335	0.000538	CcSEcCtD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—FST—liver cancer	0.000335	0.0011	CbGpPWpGaD
Lenalidomide—Visual impairment—Doxorubicin—liver cancer	0.000334	0.000537	CcSEcCtD
Lenalidomide—Alopecia—Epirubicin—liver cancer	0.000331	0.000532	CcSEcCtD
Lenalidomide—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—JUN—liver cancer	0.00033	0.00109	CbGpPWpGaD
Lenalidomide—Mental disorder—Epirubicin—liver cancer	0.000329	0.000528	CcSEcCtD
Lenalidomide—Erythema multiforme—Doxorubicin—liver cancer	0.000328	0.000527	CcSEcCtD
Lenalidomide—Malnutrition—Epirubicin—liver cancer	0.000327	0.000525	CcSEcCtD
Lenalidomide—Erythema—Epirubicin—liver cancer	0.000327	0.000525	CcSEcCtD
Lenalidomide—ABCB1—HIF-1-alpha transcription factor network—TERT—liver cancer	0.000325	0.00107	CbGpPWpGaD
Lenalidomide—Eye disorder—Doxorubicin—liver cancer	0.000324	0.000521	CcSEcCtD
Lenalidomide—Tinnitus—Doxorubicin—liver cancer	0.000324	0.00052	CcSEcCtD
Lenalidomide—Cardiac disorder—Doxorubicin—liver cancer	0.000322	0.000517	CcSEcCtD
Lenalidomide—Flushing—Doxorubicin—liver cancer	0.000322	0.000517	CcSEcCtD
Lenalidomide—Flatulence—Epirubicin—liver cancer	0.000322	0.000517	CcSEcCtD
Lenalidomide—PTGS2—Selenium Micronutrient Network—F2—liver cancer	0.000321	0.00106	CbGpPWpGaD
Lenalidomide—Tension—Epirubicin—liver cancer	0.00032	0.000515	CcSEcCtD
Lenalidomide—Dysgeusia—Epirubicin—liver cancer	0.00032	0.000514	CcSEcCtD
Lenalidomide—PTGS2—Disease—APCS—liver cancer	0.000318	0.00105	CbGpPWpGaD
Lenalidomide—Nervousness—Epirubicin—liver cancer	0.000317	0.000509	CcSEcCtD
Lenalidomide—Back pain—Epirubicin—liver cancer	0.000316	0.000507	CcSEcCtD
Lenalidomide—Angiopathy—Doxorubicin—liver cancer	0.000315	0.000506	CcSEcCtD
Lenalidomide—Muscle spasms—Epirubicin—liver cancer	0.000314	0.000504	CcSEcCtD
Lenalidomide—Immune system disorder—Doxorubicin—liver cancer	0.000313	0.000504	CcSEcCtD
Lenalidomide—Mediastinal disorder—Doxorubicin—liver cancer	0.000313	0.000502	CcSEcCtD
Lenalidomide—Chills—Doxorubicin—liver cancer	0.000311	0.0005	CcSEcCtD
Lenalidomide—Arrhythmia—Doxorubicin—liver cancer	0.00031	0.000498	CcSEcCtD
Lenalidomide—PTGS2—Aryl Hydrocarbon Receptor—VEGFA—liver cancer	0.000309	0.00102	CbGpPWpGaD
Lenalidomide—Vision blurred—Epirubicin—liver cancer	0.000308	0.000494	CcSEcCtD
Lenalidomide—Alopecia—Doxorubicin—liver cancer	0.000307	0.000493	CcSEcCtD
Lenalidomide—Mental disorder—Doxorubicin—liver cancer	0.000304	0.000488	CcSEcCtD
Lenalidomide—Ill-defined disorder—Epirubicin—liver cancer	0.000303	0.000487	CcSEcCtD
Lenalidomide—Malnutrition—Doxorubicin—liver cancer	0.000302	0.000485	CcSEcCtD
Lenalidomide—Erythema—Doxorubicin—liver cancer	0.000302	0.000485	CcSEcCtD
Lenalidomide—Anaemia—Epirubicin—liver cancer	0.000302	0.000485	CcSEcCtD
Lenalidomide—Agitation—Epirubicin—liver cancer	0.0003	0.000482	CcSEcCtD
Lenalidomide—Flatulence—Doxorubicin—liver cancer	0.000298	0.000478	CcSEcCtD
Lenalidomide—Tension—Doxorubicin—liver cancer	0.000296	0.000476	CcSEcCtD
Lenalidomide—Dysgeusia—Doxorubicin—liver cancer	0.000296	0.000475	CcSEcCtD
Lenalidomide—Malaise—Epirubicin—liver cancer	0.000294	0.000473	CcSEcCtD
Lenalidomide—Nervousness—Doxorubicin—liver cancer	0.000293	0.000471	CcSEcCtD
Lenalidomide—Vertigo—Epirubicin—liver cancer	0.000293	0.000471	CcSEcCtD
Lenalidomide—Syncope—Epirubicin—liver cancer	0.000293	0.00047	CcSEcCtD
Lenalidomide—Leukopenia—Epirubicin—liver cancer	0.000292	0.00047	CcSEcCtD
Lenalidomide—Back pain—Doxorubicin—liver cancer	0.000292	0.000469	CcSEcCtD
Lenalidomide—Muscle spasms—Doxorubicin—liver cancer	0.00029	0.000467	CcSEcCtD
Lenalidomide—PTGS2—Signaling mediated by p38-alpha and p38-beta—TP53—liver cancer	0.00029	0.000955	CbGpPWpGaD
Lenalidomide—Palpitations—Epirubicin—liver cancer	0.000289	0.000464	CcSEcCtD
Lenalidomide—Loss of consciousness—Epirubicin—liver cancer	0.000287	0.000461	CcSEcCtD
Lenalidomide—CDH5—Signaling Pathways—PRKCE—liver cancer	0.000287	0.000943	CbGpPWpGaD
Lenalidomide—Cough—Epirubicin—liver cancer	0.000285	0.000458	CcSEcCtD
Lenalidomide—Vision blurred—Doxorubicin—liver cancer	0.000285	0.000457	CcSEcCtD
Lenalidomide—PTGS2—Aryl Hydrocarbon Receptor—MYC—liver cancer	0.000284	0.000935	CbGpPWpGaD
Lenalidomide—Hypertension—Epirubicin—liver cancer	0.000282	0.000453	CcSEcCtD
Lenalidomide—Ill-defined disorder—Doxorubicin—liver cancer	0.00028	0.00045	CcSEcCtD
Lenalidomide—Anaemia—Doxorubicin—liver cancer	0.000279	0.000449	CcSEcCtD
Lenalidomide—Chest pain—Epirubicin—liver cancer	0.000278	0.000447	CcSEcCtD
Lenalidomide—Myalgia—Epirubicin—liver cancer	0.000278	0.000447	CcSEcCtD
Lenalidomide—Arthralgia—Epirubicin—liver cancer	0.000278	0.000447	CcSEcCtD
Lenalidomide—Agitation—Doxorubicin—liver cancer	0.000278	0.000446	CcSEcCtD
Lenalidomide—Anxiety—Epirubicin—liver cancer	0.000277	0.000445	CcSEcCtD
Lenalidomide—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—liver cancer	0.000276	0.000443	CcSEcCtD
Lenalidomide—Discomfort—Epirubicin—liver cancer	0.000275	0.000441	CcSEcCtD
Lenalidomide—Malaise—Doxorubicin—liver cancer	0.000272	0.000438	CcSEcCtD
Lenalidomide—Dry mouth—Epirubicin—liver cancer	0.000272	0.000437	CcSEcCtD
Lenalidomide—CDH5—Signaling Pathways—IGF2—liver cancer	0.000272	0.000894	CbGpPWpGaD
Lenalidomide—Vertigo—Doxorubicin—liver cancer	0.000271	0.000436	CcSEcCtD
Lenalidomide—Syncope—Doxorubicin—liver cancer	0.000271	0.000435	CcSEcCtD
Lenalidomide—Leukopenia—Doxorubicin—liver cancer	0.00027	0.000434	CcSEcCtD
Lenalidomide—Confusional state—Epirubicin—liver cancer	0.000269	0.000432	CcSEcCtD
Lenalidomide—PTGS2—Selenium Micronutrient Network—SERPINE1—liver cancer	0.000267	0.000879	CbGpPWpGaD
Lenalidomide—Palpitations—Doxorubicin—liver cancer	0.000267	0.000429	CcSEcCtD
Lenalidomide—PTGS2—Selenium Micronutrient Network—ALB—liver cancer	0.000266	0.000877	CbGpPWpGaD
Lenalidomide—Oedema—Epirubicin—liver cancer	0.000266	0.000428	CcSEcCtD
Lenalidomide—Loss of consciousness—Doxorubicin—liver cancer	0.000266	0.000427	CcSEcCtD
Lenalidomide—Infection—Epirubicin—liver cancer	0.000265	0.000425	CcSEcCtD
Lenalidomide—PTGS2—Aryl Hydrocarbon Receptor—TNF—liver cancer	0.000264	0.00087	CbGpPWpGaD
Lenalidomide—Cough—Doxorubicin—liver cancer	0.000264	0.000424	CcSEcCtD
Lenalidomide—PTGS2—Aryl Hydrocarbon Receptor—KRAS—liver cancer	0.000262	0.000863	CbGpPWpGaD
Lenalidomide—Shock—Epirubicin—liver cancer	0.000262	0.000421	CcSEcCtD
Lenalidomide—Nervous system disorder—Epirubicin—liver cancer	0.000261	0.00042	CcSEcCtD
Lenalidomide—Thrombocytopenia—Epirubicin—liver cancer	0.000261	0.000419	CcSEcCtD
Lenalidomide—Hypertension—Doxorubicin—liver cancer	0.000261	0.000419	CcSEcCtD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—HNF4A—liver cancer	0.00026	0.000857	CbGpPWpGaD
Lenalidomide—Tachycardia—Epirubicin—liver cancer	0.00026	0.000418	CcSEcCtD
Lenalidomide—Skin disorder—Epirubicin—liver cancer	0.000259	0.000416	CcSEcCtD
Lenalidomide—PTGS2—C-MYB transcription factor network—CDKN2A—liver cancer	0.000259	0.000852	CbGpPWpGaD
Lenalidomide—Hyperhidrosis—Epirubicin—liver cancer	0.000258	0.000414	CcSEcCtD
Lenalidomide—Myalgia—Doxorubicin—liver cancer	0.000257	0.000413	CcSEcCtD
Lenalidomide—Arthralgia—Doxorubicin—liver cancer	0.000257	0.000413	CcSEcCtD
Lenalidomide—Chest pain—Doxorubicin—liver cancer	0.000257	0.000413	CcSEcCtD
Lenalidomide—Anxiety—Doxorubicin—liver cancer	0.000256	0.000412	CcSEcCtD
Lenalidomide—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—liver cancer	0.000255	0.00041	CcSEcCtD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—HPGDS—liver cancer	0.000255	0.00084	CbGpPWpGaD
Lenalidomide—Discomfort—Doxorubicin—liver cancer	0.000254	0.000408	CcSEcCtD
Lenalidomide—Anorexia—Epirubicin—liver cancer	0.000254	0.000408	CcSEcCtD
Lenalidomide—CDH5—Signaling Pathways—CSF2—liver cancer	0.000254	0.000835	CbGpPWpGaD
Lenalidomide—Dry mouth—Doxorubicin—liver cancer	0.000252	0.000404	CcSEcCtD
Lenalidomide—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—CDKN1B—liver cancer	0.00025	0.000823	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—H2AFX—liver cancer	0.00025	0.000823	CbGpPWpGaD
Lenalidomide—Hypotension—Epirubicin—liver cancer	0.000249	0.0004	CcSEcCtD
Lenalidomide—Confusional state—Doxorubicin—liver cancer	0.000249	0.000399	CcSEcCtD
Lenalidomide—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—TNF—liver cancer	0.000247	0.000814	CbGpPWpGaD
Lenalidomide—Oedema—Doxorubicin—liver cancer	0.000247	0.000396	CcSEcCtD
Lenalidomide—Infection—Doxorubicin—liver cancer	0.000245	0.000394	CcSEcCtD
Lenalidomide—Musculoskeletal discomfort—Epirubicin—liver cancer	0.000243	0.00039	CcSEcCtD
Lenalidomide—Shock—Doxorubicin—liver cancer	0.000243	0.00039	CcSEcCtD
Lenalidomide—Nervous system disorder—Doxorubicin—liver cancer	0.000242	0.000388	CcSEcCtD
Lenalidomide—Thrombocytopenia—Doxorubicin—liver cancer	0.000241	0.000388	CcSEcCtD
Lenalidomide—Insomnia—Epirubicin—liver cancer	0.000241	0.000387	CcSEcCtD
Lenalidomide—Tachycardia—Doxorubicin—liver cancer	0.000241	0.000387	CcSEcCtD
Lenalidomide—Skin disorder—Doxorubicin—liver cancer	0.000239	0.000385	CcSEcCtD
Lenalidomide—Paraesthesia—Epirubicin—liver cancer	0.000239	0.000384	CcSEcCtD
Lenalidomide—Hyperhidrosis—Doxorubicin—liver cancer	0.000238	0.000383	CcSEcCtD
Lenalidomide—ABCB1—HIF-1-alpha transcription factor network—SERPINE1—liver cancer	0.000238	0.000784	CbGpPWpGaD
Lenalidomide—Dyspnoea—Epirubicin—liver cancer	0.000238	0.000382	CcSEcCtD
Lenalidomide—Somnolence—Epirubicin—liver cancer	0.000237	0.000381	CcSEcCtD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—ABL1—liver cancer	0.000237	0.000779	CbGpPWpGaD
Lenalidomide—Anorexia—Doxorubicin—liver cancer	0.000235	0.000378	CcSEcCtD
Lenalidomide—Dyspepsia—Epirubicin—liver cancer	0.000235	0.000377	CcSEcCtD
Lenalidomide—PTGS2—Metabolism of lipids and lipoproteins—CPT1B—liver cancer	0.000233	0.000768	CbGpPWpGaD
Lenalidomide—Decreased appetite—Epirubicin—liver cancer	0.000232	0.000372	CcSEcCtD
Lenalidomide—Hypotension—Doxorubicin—liver cancer	0.00023	0.00037	CcSEcCtD
Lenalidomide—Gastrointestinal disorder—Epirubicin—liver cancer	0.00023	0.00037	CcSEcCtD
Lenalidomide—Fatigue—Epirubicin—liver cancer	0.00023	0.000369	CcSEcCtD
Lenalidomide—PTGS2—C-MYB transcription factor network—CDKN1B—liver cancer	0.000229	0.000754	CbGpPWpGaD
Lenalidomide—Pain—Epirubicin—liver cancer	0.000228	0.000366	CcSEcCtD
Lenalidomide—Constipation—Epirubicin—liver cancer	0.000228	0.000366	CcSEcCtD
Lenalidomide—CDH5—Signaling Pathways—TERT—liver cancer	0.000226	0.000744	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism of lipids and lipoproteins—NR1H4—liver cancer	0.000225	0.000741	CbGpPWpGaD
Lenalidomide—Musculoskeletal discomfort—Doxorubicin—liver cancer	0.000225	0.000361	CcSEcCtD
Lenalidomide—Insomnia—Doxorubicin—liver cancer	0.000223	0.000358	CcSEcCtD
Lenalidomide—PTGS2—Aryl Hydrocarbon Receptor—HRAS—liver cancer	0.000223	0.000734	CbGpPWpGaD
Lenalidomide—Paraesthesia—Doxorubicin—liver cancer	0.000221	0.000356	CcSEcCtD
Lenalidomide—Dyspnoea—Doxorubicin—liver cancer	0.00022	0.000353	CcSEcCtD
Lenalidomide—Feeling abnormal—Epirubicin—liver cancer	0.00022	0.000353	CcSEcCtD
Lenalidomide—Somnolence—Doxorubicin—liver cancer	0.000219	0.000352	CcSEcCtD
Lenalidomide—PTGS2—C-MYB transcription factor network—CCND1—liver cancer	0.000219	0.00072	CbGpPWpGaD
Lenalidomide—Gastrointestinal pain—Epirubicin—liver cancer	0.000218	0.00035	CcSEcCtD
Lenalidomide—Dyspepsia—Doxorubicin—liver cancer	0.000217	0.000349	CcSEcCtD
Lenalidomide—Decreased appetite—Doxorubicin—liver cancer	0.000214	0.000344	CcSEcCtD
Lenalidomide—Gastrointestinal disorder—Doxorubicin—liver cancer	0.000213	0.000342	CcSEcCtD
Lenalidomide—Fatigue—Doxorubicin—liver cancer	0.000213	0.000342	CcSEcCtD
Lenalidomide—Urticaria—Epirubicin—liver cancer	0.000212	0.00034	CcSEcCtD
Lenalidomide—PTGS2—C-MYB transcription factor network—CDKN1A—liver cancer	0.000212	0.000696	CbGpPWpGaD
Lenalidomide—Pain—Doxorubicin—liver cancer	0.000211	0.000339	CcSEcCtD
Lenalidomide—Constipation—Doxorubicin—liver cancer	0.000211	0.000339	CcSEcCtD
Lenalidomide—Abdominal pain—Epirubicin—liver cancer	0.000211	0.000338	CcSEcCtD
Lenalidomide—Body temperature increased—Epirubicin—liver cancer	0.000211	0.000338	CcSEcCtD
Lenalidomide—CDH5—Signaling Pathways—KDR—liver cancer	0.000207	0.00068	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—MAPK14—liver cancer	0.000205	0.000676	CbGpPWpGaD
Lenalidomide—Feeling abnormal—Doxorubicin—liver cancer	0.000203	0.000326	CcSEcCtD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—PCNA—liver cancer	0.000203	0.000668	CbGpPWpGaD
Lenalidomide—Gastrointestinal pain—Doxorubicin—liver cancer	0.000202	0.000324	CcSEcCtD
Lenalidomide—CDH5—Signaling Pathways—ESR1—liver cancer	0.000201	0.000663	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—F2—liver cancer	0.000199	0.000655	CbGpPWpGaD
Lenalidomide—Hypersensitivity—Epirubicin—liver cancer	0.000196	0.000315	CcSEcCtD
Lenalidomide—Urticaria—Doxorubicin—liver cancer	0.000196	0.000315	CcSEcCtD
Lenalidomide—Abdominal pain—Doxorubicin—liver cancer	0.000195	0.000313	CcSEcCtD
Lenalidomide—Body temperature increased—Doxorubicin—liver cancer	0.000195	0.000313	CcSEcCtD
Lenalidomide—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—MYC—liver cancer	0.000191	0.00063	CbGpPWpGaD
Lenalidomide—Asthenia—Epirubicin—liver cancer	0.000191	0.000307	CcSEcCtD
Lenalidomide—CDH5—Signaling Pathways—PIK3CG—liver cancer	0.00019	0.000627	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—APC—liver cancer	0.00019	0.000627	CbGpPWpGaD
Lenalidomide—Pruritus—Epirubicin—liver cancer	0.000189	0.000303	CcSEcCtD
Lenalidomide—ABCB1—HIF-1-alpha transcription factor network—JUN—liver cancer	0.000188	0.000617	CbGpPWpGaD
Lenalidomide—Diarrhoea—Epirubicin—liver cancer	0.000182	0.000293	CcSEcCtD
Lenalidomide—Hypersensitivity—Doxorubicin—liver cancer	0.000182	0.000292	CcSEcCtD
Lenalidomide—CDH5—Signaling Pathways—BRAF—liver cancer	0.000179	0.000589	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—MAPK14—liver cancer	0.000178	0.000586	CbGpPWpGaD
Lenalidomide—Asthenia—Doxorubicin—liver cancer	0.000177	0.000284	CcSEcCtD
Lenalidomide—Dizziness—Epirubicin—liver cancer	0.000176	0.000283	CcSEcCtD
Lenalidomide—PTGS2—C-MYB transcription factor network—MYC—liver cancer	0.000175	0.000577	CbGpPWpGaD
Lenalidomide—ABCB1—Transmembrane transport of small molecules—SLC11A2—liver cancer	0.000175	0.000577	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—ESR1—liver cancer	0.000175	0.000575	CbGpPWpGaD
Lenalidomide—PTGS2—Spinal Cord Injury—CDKN1B—liver cancer	0.000175	0.000575	CbGpPWpGaD
Lenalidomide—Pruritus—Doxorubicin—liver cancer	0.000174	0.00028	CcSEcCtD
Lenalidomide—PTGS2—Metabolism of lipids and lipoproteins—CRABP1—liver cancer	0.000172	0.000566	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—UGDH—liver cancer	0.000172	0.000565	CbGpPWpGaD
Lenalidomide—PTGS2—Spinal Cord Injury—CASP3—liver cancer	0.000171	0.000563	CbGpPWpGaD
Lenalidomide—PTGS2—Spinal Cord Injury—IL2—liver cancer	0.000171	0.000562	CbGpPWpGaD
Lenalidomide—Vomiting—Epirubicin—liver cancer	0.000169	0.000272	CcSEcCtD
Lenalidomide—Diarrhoea—Doxorubicin—liver cancer	0.000169	0.000271	CcSEcCtD
Lenalidomide—Rash—Epirubicin—liver cancer	0.000168	0.00027	CcSEcCtD
Lenalidomide—Dermatitis—Epirubicin—liver cancer	0.000168	0.00027	CcSEcCtD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—ABL1—liver cancer	0.000168	0.000552	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—PIK3CD—liver cancer	0.000167	0.000551	CbGpPWpGaD
Lenalidomide—ABCB1—Transmembrane transport of small molecules—SLC40A1—liver cancer	0.000167	0.000551	CbGpPWpGaD
Lenalidomide—ABCB1—Allograft Rejection—CASP3—liver cancer	0.000167	0.00055	CbGpPWpGaD
Lenalidomide—ABCB1—Allograft Rejection—IL2—liver cancer	0.000167	0.00055	CbGpPWpGaD
Lenalidomide—Headache—Epirubicin—liver cancer	0.000167	0.000268	CcSEcCtD
Lenalidomide—PTGS2—Spinal Cord Injury—CCND1—liver cancer	0.000167	0.000548	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—SERPINE1—liver cancer	0.000166	0.000545	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—APC—liver cancer	0.000165	0.000544	CbGpPWpGaD
Lenalidomide—ABCB1—HIF-1-alpha transcription factor network—VEGFA—liver cancer	0.000164	0.000539	CbGpPWpGaD
Lenalidomide—Dizziness—Doxorubicin—liver cancer	0.000163	0.000262	CcSEcCtD
Lenalidomide—PTGS2—C-MYB transcription factor network—KRAS—liver cancer	0.000162	0.000533	CbGpPWpGaD
Lenalidomide—PTGS2—Spinal Cord Injury—MMP9—liver cancer	0.000162	0.000532	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—EPT1—liver cancer	0.000161	0.000531	CbGpPWpGaD
Lenalidomide—ABCB1—Transmembrane transport of small molecules—ATP7B—liver cancer	0.00016	0.000528	CbGpPWpGaD
Lenalidomide—ABCB1—Transmembrane transport of small molecules—ANXA2—liver cancer	0.00016	0.000528	CbGpPWpGaD
Lenalidomide—Nausea—Epirubicin—liver cancer	0.000158	0.000254	CcSEcCtD
Lenalidomide—PTGS2—Selenium Micronutrient Network—TNF—liver cancer	0.000157	0.000518	CbGpPWpGaD
Lenalidomide—Vomiting—Doxorubicin—liver cancer	0.000157	0.000252	CcSEcCtD
Lenalidomide—Rash—Doxorubicin—liver cancer	0.000155	0.00025	CcSEcCtD
Lenalidomide—Dermatitis—Doxorubicin—liver cancer	0.000155	0.00025	CcSEcCtD
Lenalidomide—Headache—Doxorubicin—liver cancer	0.000154	0.000248	CcSEcCtD
Lenalidomide—PTGS2—Metabolism—TAT—liver cancer	0.000153	0.000503	CbGpPWpGaD
Lenalidomide—ABCB1—Transmembrane transport of small molecules—NR1H4—liver cancer	0.000152	0.000499	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism of lipids and lipoproteins—HPGDS—liver cancer	0.00015	0.000495	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—RAF1—liver cancer	0.000149	0.000492	CbGpPWpGaD
Lenalidomide—Nausea—Doxorubicin—liver cancer	0.000146	0.000235	CcSEcCtD
Lenalidomide—CDH5—Signaling Pathways—MTOR—liver cancer	0.000146	0.00048	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—PIK3CB—liver cancer	0.000146	0.00048	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—PCNA—liver cancer	0.000144	0.000474	CbGpPWpGaD
Lenalidomide—ABCB1—Allograft Rejection—VEGFA—liver cancer	0.000142	0.000467	CbGpPWpGaD
Lenalidomide—PTGS2—C-MYB transcription factor network—HRAS—liver cancer	0.000138	0.000453	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—CDKN1B—liver cancer	0.000137	0.000451	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—CASP3—liver cancer	0.000134	0.000442	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—IL2—liver cancer	0.000134	0.000441	CbGpPWpGaD
Lenalidomide—PTGS2—Spinal Cord Injury—MYC—liver cancer	0.000134	0.00044	CbGpPWpGaD
Lenalidomide—PTGS2—Spinal Cord Injury—TGFB1—liver cancer	0.000133	0.000439	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—CCND1—liver cancer	0.000131	0.00043	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—JUN—liver cancer	0.00013	0.000429	CbGpPWpGaD
Lenalidomide—ABCB1—Allograft Rejection—TGFB1—liver cancer	0.00013	0.000429	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—RAF1—liver cancer	0.00013	0.000427	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—CTNNB1—liver cancer	0.000129	0.000426	CbGpPWpGaD
Lenalidomide—PTGS2—Selenium Micronutrient Network—IL6—liver cancer	0.000127	0.000418	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—MMP9—liver cancer	0.000127	0.000417	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—CDKN1A—liver cancer	0.000126	0.000416	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—MAPK14—liver cancer	0.000126	0.000416	CbGpPWpGaD
Lenalidomide—PTGS2—Spinal Cord Injury—TNF—liver cancer	0.000124	0.00041	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—LTF—liver cancer	0.000124	0.000408	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—ESR1—liver cancer	0.000124	0.000408	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—MAPK8—liver cancer	0.000123	0.000406	CbGpPWpGaD
Lenalidomide—ABCB1—Allograft Rejection—TNF—liver cancer	0.000122	0.0004	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—UGDH—liver cancer	0.000122	0.0004	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—CDKN1B—liver cancer	0.000119	0.000391	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—APC—liver cancer	0.000117	0.000385	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—CASP3—liver cancer	0.000116	0.000383	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—EPT1—liver cancer	0.000114	0.000376	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—VEGFA—liver cancer	0.000114	0.000375	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—CCND1—liver cancer	0.000113	0.000373	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—JUN—liver cancer	0.000113	0.000372	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—STAT3—liver cancer	0.000113	0.000371	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism of lipids and lipoproteins—GGT1—liver cancer	0.000113	0.00037	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—CTNNB1—liver cancer	0.000112	0.000369	CbGpPWpGaD
Lenalidomide—PTGS2—Spinal Cord Injury—TP53—liver cancer	0.00011	0.000361	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—CDKN1A—liver cancer	0.00011	0.000361	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—TAT—liver cancer	0.000108	0.000357	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—MAPK8—liver cancer	0.000107	0.000352	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—MYC—liver cancer	0.000105	0.000345	CbGpPWpGaD
Lenalidomide—ABCB1—HIF-1-alpha transcription factor network—AKT1—liver cancer	0.000105	0.000344	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—TGFB1—liver cancer	0.000105	0.000344	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—CPT1B—liver cancer	0.000104	0.000342	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—GLUL—liver cancer	0.000104	0.000342	CbGpPWpGaD
Lenalidomide—PTGS2—Spinal Cord Injury—IL6—liver cancer	0.0001	0.000331	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—NR1H4—liver cancer	0.0001	0.00033	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—VEGFA—liver cancer	9.88e-05	0.000325	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—GSTA3—liver cancer	9.85e-05	0.000324	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—KRAS—liver cancer	9.68e-05	0.000319	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—ALDOB—liver cancer	9.59e-05	0.000316	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—RAF1—liver cancer	9.19e-05	0.000303	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—MYC—liver cancer	9.09e-05	0.000299	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—TGFB1—liver cancer	9.07e-05	0.000298	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—GSTA4—liver cancer	9.01e-05	0.000297	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—PIK3CA—liver cancer	8.89e-05	0.000293	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism of lipids and lipoproteins—CYP1A1—liver cancer	8.81e-05	0.00029	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—GSTA2—liver cancer	8.78e-05	0.000289	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—TP53—liver cancer	8.6e-05	0.000283	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—GSTA1—liver cancer	8.47e-05	0.000279	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—TNF—liver cancer	8.47e-05	0.000279	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—CDKN1B—liver cancer	8.42e-05	0.000277	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—KRAS—liver cancer	8.4e-05	0.000276	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—NAT2—liver cancer	8.38e-05	0.000276	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—CASP3—liver cancer	8.25e-05	0.000272	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—HRAS—liver cancer	8.23e-05	0.000271	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism of lipids and lipoproteins—PPARA—liver cancer	8.05e-05	0.000265	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—CCND1—liver cancer	8.03e-05	0.000264	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—ALDOB—liver cancer	8.03e-05	0.000264	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—JUN—liver cancer	8.02e-05	0.000264	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—CTNNB1—liver cancer	7.96e-05	0.000262	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—IL6—liver cancer	7.88e-05	0.000259	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—CDKN1A—liver cancer	7.77e-05	0.000256	CbGpPWpGaD
Lenalidomide—ABCB1—Transmembrane transport of small molecules—CYCS—liver cancer	7.73e-05	0.000254	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—PIK3CA—liver cancer	7.72e-05	0.000254	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—CRABP1—liver cancer	7.66e-05	0.000252	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—MAPK8—liver cancer	7.58e-05	0.00025	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—ADAM17—liver cancer	7.58e-05	0.00025	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—TP53—liver cancer	7.46e-05	0.000246	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—CPT1B—liver cancer	7.37e-05	0.000242	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—GLUL—liver cancer	7.37e-05	0.000242	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—AKT1—liver cancer	7.27e-05	0.000239	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—PSMD10—liver cancer	7.13e-05	0.000235	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—PSMA4—liver cancer	7.13e-05	0.000235	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—NR1H4—liver cancer	7.1e-05	0.000234	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—liver cancer	7e-05	0.000231	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—GSTA3—liver cancer	6.98e-05	0.00023	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—GOT2—liver cancer	6.93e-05	0.000228	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism of lipids and lipoproteins—PIK3CG—liver cancer	6.9e-05	0.000227	CbGpPWpGaD
Lenalidomide—ABCB1—Transmembrane transport of small molecules—HMOX1—liver cancer	6.72e-05	0.000221	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—HPGDS—liver cancer	6.7e-05	0.00022	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism of lipids and lipoproteins—PPARG—liver cancer	6.66e-05	0.000219	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—liver cancer	6.44e-05	0.000212	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—TGFB1—liver cancer	6.43e-05	0.000212	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—GSTA4—liver cancer	6.39e-05	0.00021	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—AKT1—liver cancer	6.3e-05	0.000207	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—GSTA2—liver cancer	6.22e-05	0.000205	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism of lipids and lipoproteins—PIK3CD—liver cancer	6.06e-05	0.0002	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—GSTA1—liver cancer	6.01e-05	0.000198	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—liver cancer	6e-05	0.000198	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism of lipids and lipoproteins—ALB—liver cancer	5.99e-05	0.000197	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—GOT1—liver cancer	5.98e-05	0.000197	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—PSMA4—liver cancer	5.97e-05	0.000196	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—PSMD10—liver cancer	5.97e-05	0.000196	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—liver cancer	5.95e-05	0.000196	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—NAT2—liver cancer	5.94e-05	0.000195	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—GOT2—liver cancer	5.81e-05	0.000191	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—ALDOB—liver cancer	5.69e-05	0.000187	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—PRKCE—liver cancer	5.52e-05	0.000182	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—PIK3CA—liver cancer	5.47e-05	0.00018	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—CYP2E1—liver cancer	5.46e-05	0.00018	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—CRABP1—liver cancer	5.43e-05	0.000179	CbGpPWpGaD
Lenalidomide—ABCB1—Transmembrane transport of small molecules—PPARA—liver cancer	5.43e-05	0.000179	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—liver cancer	5.29e-05	0.000174	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism of lipids and lipoproteins—PIK3CB—liver cancer	5.29e-05	0.000174	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—CYCS—liver cancer	5.11e-05	0.000168	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—GOT1—liver cancer	5.01e-05	0.000165	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—GGT1—liver cancer	5.01e-05	0.000165	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—H2AFX—liver cancer	4.81e-05	0.000158	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—HPGDS—liver cancer	4.75e-05	0.000156	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—GSTP1—liver cancer	4.5e-05	0.000148	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—liver cancer	4.47e-05	0.000147	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—HMOX1—liver cancer	4.44e-05	0.000146	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—MTHFR—liver cancer	4.37e-05	0.000144	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—TERT—liver cancer	4.35e-05	0.000143	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—PSMD10—liver cancer	4.23e-05	0.000139	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—PSMA4—liver cancer	4.23e-05	0.000139	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—GSTM1—liver cancer	4.14e-05	0.000136	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—GOT2—liver cancer	4.12e-05	0.000135	CbGpPWpGaD
Lenalidomide—ABCB1—Transmembrane transport of small molecules—ALB—liver cancer	4.03e-05	0.000133	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—CYP1A1—liver cancer	3.92e-05	0.000129	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—CYP2E1—liver cancer	3.87e-05	0.000127	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—APC—liver cancer	3.67e-05	0.000121	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—MTHFR—liver cancer	3.66e-05	0.00012	CbGpPWpGaD
Lenalidomide—ABCB1—Transmembrane transport of small molecules—RAF1—liver cancer	3.65e-05	0.00012	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—CYCS—liver cancer	3.62e-05	0.000119	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—PPARA—liver cancer	3.59e-05	0.000118	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—GOT1—liver cancer	3.55e-05	0.000117	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—GGT1—liver cancer	3.55e-05	0.000117	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—BRAF—liver cancer	3.45e-05	0.000113	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—PIK3CD—liver cancer	3.22e-05	0.000106	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism of lipids and lipoproteins—PIK3CA—liver cancer	3.22e-05	0.000106	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—GSTP1—liver cancer	3.19e-05	0.000105	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—SERPINE1—liver cancer	3.19e-05	0.000105	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—HMOX1—liver cancer	3.15e-05	0.000104	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—PIK3CG—liver cancer	3.07e-05	0.000101	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—PPARG—liver cancer	2.96e-05	9.76e-05	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—GSTM1—liver cancer	2.93e-05	9.65e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—RAF1—liver cancer	2.88e-05	9.48e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—MTOR—liver cancer	2.81e-05	9.25e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—PIK3CB—liver cancer	2.81e-05	9.25e-05	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—CYP1A1—liver cancer	2.78e-05	9.15e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—PIK3CD—liver cancer	2.7e-05	8.89e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—ALB—liver cancer	2.67e-05	8.78e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—CDKN1B—liver cancer	2.64e-05	8.68e-05	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—MTHFR—liver cancer	2.59e-05	8.53e-05	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—PPARA—liver cancer	2.54e-05	8.37e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—CTNNB1—liver cancer	2.49e-05	8.2e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—CDKN1A—liver cancer	2.43e-05	8.01e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—PIK3CB—liver cancer	2.35e-05	7.75e-05	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—PIK3CG—liver cancer	2.18e-05	7.17e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—STAT3—liver cancer	2.17e-05	7.15e-05	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—PPARG—liver cancer	2.1e-05	6.92e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—MYC—liver cancer	2.02e-05	6.64e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—TGFB1—liver cancer	2.01e-05	6.63e-05	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—PIK3CD—liver cancer	1.91e-05	6.3e-05	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—ALB—liver cancer	1.89e-05	6.22e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—KRAS—liver cancer	1.87e-05	6.14e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—PIK3CA—liver cancer	1.71e-05	5.64e-05	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—PIK3CB—liver cancer	1.67e-05	5.49e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—HRAS—liver cancer	1.59e-05	5.22e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—IL6—liver cancer	1.52e-05	4.99e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—PIK3CA—liver cancer	1.43e-05	4.72e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—AKT1—liver cancer	1.4e-05	4.61e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—AKT1—liver cancer	1.17e-05	3.86e-05	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—PIK3CA—liver cancer	1.02e-05	3.35e-05	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—AKT1—liver cancer	8.31e-06	2.74e-05	CbGpPWpGaD
